A Phase III Trial of Seladelpar in Primary Biliary Cholangitis

In this Phase III, 12-month, double-blind, placebo-controlled trial, researchers randomly assigned patients who had had an inadequate response to or who had a history of unacceptable side effects with ursodeoxycholic acid to receive oral seladelpar at a dose of 10 mg daily or placebo.